Adocia SA (A89)

Overview

Adocia SA is a clinical-stage biotechnology firm, specializing in the research and development of novel formulations for pre-approved therapeutic proteins and peptides aimed at treating diabetes and other metabolic diseases. The foundation of its innovation lies in the proprietary BioChaperone technological platform, designed to enhance the molecular delivery of therapeutic proteins. With its corporate headquarters situated in Lyon, France, Adocia was founded in 2005 and has since established a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd., focusing on the development and commercialization of key insulin formulations in China, alongside other Asian and Middle Eastern territories. This collaboration underscores Adocia's commitment to extending its reach and impact in addressing the global challenge of diabetes and related metabolic conditions.

Products and Services

Adocia SA's robust product pipeline spans both clinical and preclinical stages, primarily targeting diabetes management and obesity treatment. The offerings include:

• BioChaperone Lispro U100 and U200: These are ultra-rapid acting insulin lispro formulations aimed at enhancing diabetes management by speeding up insulin absorption, distribution, and onset of action.
• BioChaperone Combo: A novel combination therapy featuring long-acting insulin glargine and rapid-acting insulin lispro, designed to simplify diabetes management by reducing the number of injections needed per day.
• BioChaperone LisPram: This product combines prandial insulin with pramlintide to potentially offer a more comprehensive management of blood sugar levels for individuals with diabetes.
• BioChaperone Glucagon: An aqueous formulation of human glucagon for the emergency treatment of severe hypoglycemia, offering a potentially life-saving solution in critical situations.
• M1Pram: A metabolite combination of insulin glargine and pramlintide, underlining Adocia's innovative approach towards creating more efficient and patient-friendly diabetes management solutions.
• Preclinical Pipeline: Adocia is also exploring products for diabetes and obesity treatment in preclinical stages, including AdoShell Islets—an implant containing islets of Langerhans, AdOral Sema—an oral delivery form of semaglutide, and BioChaperone GluExe—a combination therapy of glucagon and exenatide, highlighting the company's commitment to expanding its portfolio with novel therapeutic options.